| 21-1567 |
Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc. |
Federal Circuit |
2022-06-15 |
Denied |
35-usc-112 effective-dose efficacy-requirement federal-circuit multiple-sclerosis patent patent-law patent-specification statutory-interpretation written-description |
Is 35 U.S.C. § 112's written-description requirement met when the specification describes the invention? |
| 19-1451 |
Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. |
Federal Circuit |
2020-07-02 |
Denied |
administrative-law appointments-clause constitutional-challenge federal-circuit forfeiture ksr-international-co-v-teleflex-inc obviousness patent-act patent-law patent-trial-and-appeal-board pending-case separation-of-powers |
Whether a court can refuse to entertain a constitutional, separation-of-powers challenge based on an intervening change of law on the grounds of forfe… |
| 19A886 |
Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. |
Federal Circuit |
2020-02-07 |
Presumed Complete |
None |
|
| 18-692 |
Mylan Pharmaceuticals Inc., et al. v. UCB, Inc., et al. |
Federal Circuit |
2018-11-27 |
Denied |
35-usc-103 double-patenting federal-circuit graham-factors graham-v-john-deere invention-disclosure lead-compound-test obviousness patent-eligibility patent-law patent-law-doctrine-of-double-patenting patent-validity prior-art |
Whether a patentee may obtain a second patent on the same invention actually covered by a former patent to the same patentee |